skip to content »

Section of Atherosclerosis

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Section of Atherosclerosis and Vascular Medicine
not shown on screen

Publications 2005

  1. Hoogeveen RC, Ballantyne CM. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn 2005; 5:9–14.
  2. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005; 80:219–230.
  3. Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM. Manifestations of inflammatory arthritis are critically dependent on LFA- 1. J Immunol 2005; 174:3668–3675.
  4. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28:385–390.
  5. Wu AH, Ballantyne CM, Short BC, Torre-Amione G, Young JB, Ventura HO, Eisen HJ, Radovancevic B, Rayburn BK, Lake KD, Yancy CW Jr, Taylor DO, Mehra MR, Kubo SH, Fishbein DP, Zhao XQ, O'Brien KD. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 2005; 95:367–372.
  6. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe plus simvastatin (VytorinTM) versus atorvastatin in patients with hypercholesterolemia: The Vytorin versus Atorvastatin (VYVA) Study. Am Heart J 2005; 149:464–475.
  7. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611–1619.
  8. Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW, Ballantyne CM. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma using the Luminex-100™ system. Clin Chem 2005; 51:1102–1109.
  9. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless LE. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28:2013–2018.
  10. Hoogeveen, RC, Morrison, A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities Study. Atherosclerosis 2005;183:301–307.
  11. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479–2484.
  12. Fordis M, King JE, Ballantyne CM, Jones PH, Schneider KH, Spann SJ, Greenberg SB, Greisinger AJ. Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA 2005;294:1043–1051.
  13. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E- Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556–563.
  14. Abe Y, Bui-Thanh NA, Ballantyne CM, Burns AR. Extra domain A and type III connecting segment of fibronectin in assembly and cleavage. Biochem Biophys Res Commun 2005;338:1640–1647.
  15. Sturgeon JD, Folsom AR, Bray MS, Boerwinkle E, Ballantyne CM, for the Atherosclerosis Risk in Communities Study Investigators. Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. Stroke 2005;36:2484–2486.
  16. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A Comparative study with rosuvastatin in subjects with Metabolic Syndrome: results of the COMETS study. Eur Heart J 2005;26:2664–2672.
  17. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005;26:2224–2231.
  18. Barter PJ, Ballantyne CM. Discussion. Int J Clin Pract 59:Suppl s148, 2005; (148):15–16.
  19. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005; 6:21–29.
  20. Nambi V, Ballantyne CM. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Curr Atheroscler Rep 2005; 7:22–28.
  21. Nambi V, Ballantyne CM. Fat, fit, and leading the charge: the evolution of measuring high- density lipoprotein subpopulations. Arterioscler Thromb Vasc Biol 2005;25:2013–2015.
  22. Ballantyne CM. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Am J Cardiol 2005;96:14K–19K.
  23. Vasudevan AR, Ballantyne CM. Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus. Clin Cornerstone. 2005;7(2- 3):7-16.
  24. Ballantyne CM. Cholesterol, lipids, and statins. Tex Heart Inst J 2005;32:378-379.
  25. McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB. LDL-C goal attainment with ezetimibe plus simvastatin co administration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed 2005;7(3):3.

E-mail this page to a friend